anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Drug-induced cardiotoxicity is a primary concern in both drug development and clinical practice. Although the heart is not a common target for adverse drug reactions, some drugs still cause various adverse cardiac events, with sometimes severe consequences. Direct cardiac toxicity encompasses functional and structural changes of the cardiovascular system due to possible exposure to medicines. This phenomenon extends beyond cardiovascular drugs to include non-cardiovascular drugs including anticancer drugs such as tyrosine kinase inhibitors, anthracyclines and immune checkpoint inhibitors (ICIs), as well as various antipsychotics, venlafaxine, and even some antibiotics (such as macrolides). Cardiac ADRs comprise an array of effects, ranging from heart failure and myocardial ischemia to valvular disease, thrombosis, myocarditis, pericarditis, arrhythmias, and conduction abnormalities. The underlying mechanisms may include disturbances of ionic processes, induction of cellular damage via impaired mitochondrial function, and even hypercoagulability. To mitigate the impact of drug-induced cardiotoxicity, multi-stage evaluation guidelines have been established, following the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines for in vitro and in vivo testing. Despite preclinical safeguards, post-marketing surveillance remains critical, as certain cardiotoxic drugs may escape initial scrutiny. Indeed, historical data show that cardiovascular ADRs contribute to almost 10% of market withdrawals. The impact of drug-induced cardiotoxicity on cardiac issues, particularly heart failure, is often underestimated, with incidence rates ranging from 11.0% to over 20.0%. We here comprehensively examine different patterns of drug-induced cardiotoxicity, highlighting current concerns and emerging pharmacovigilance signals. Understanding the underlying mechanisms and the associated risk factors is critical in order to promptly identify, effectively manage, and proactively prevent drug-induced cardiac adverse events. Collaborative efforts between physicians and cardiologists, coupled with thorough assessment and close monitoring, are essential to ensuring patient safety in the face of potential drug-induced cardiotoxicity.
PURPOSE:To provide the titled composition obtained by compounding inorganic clay mineral in combination with a photo-sensitive element, and exhibiting excellent storage stability against heat and light even in the case of compounding to a base of cosmetic, drug, etc. CONSTITUTION:The objective composition contians 1pt.wt. of photo-sensitive element No.201 and >=1pt.wt. of inorganic clay mineral, and if necessay other additives used generally in the field of cosmetic, medicine, etc., such as surfactant, oil, UV-absorber, preservative, organic solvent, drug, perfumery, etc. The photo-sensitive element has sterilization and disinfection activity, is effective to chapping, pimple, crack, frostbits, spot, freckle, etc., and gives smooth and nourished skin. The storage stability of the element can be improved by the combined use with an inorganic clay mineral (bentonite). The amount of the photo-sensitive element is preferably 0.0001-0.1wt% based on the whole composition.
Effective parts of corydalis impatiens and preparing method and application thereof belong to the field of plant extract technology, which is selected from the total alkaloid extract of corydalis impatiens. The herb is smashed and added into a ethanol solution with the mass percentage of 65% - 95% for reflux extraction. And the yielded extract solution is concentrated and dried to obtain the extract, in which a hydrochloric acid aqueous solution is added with a mass concentration of 2%. After removal of the fat-soluble impurities, the pH is adjusted to 9 to 10 by adding some ammonium hydroxide. Finally, the extract is obtained by multiple extractions with chloroform, and is concentrated and dried to obtain the total alkaloid extract of corydalis impatiens. The effective part of corydalis impatiens in this invention can be used for preparing anti-tumor drugs, for the application of the effective part of corydalis impatiens in the preparation of drugs for inhibiting HDAC1 enzyme.
The present disclosure provides polypeptide dimers and polypeptides for improving cellular immunotherapy. Disclosed embodiments include polypeptide dimers (referred-to herein as TCR/CARs) that confer to a host cell (e.g. a T cell) target-specificity of a CAR while leveraging natural T cell signaling properties. TCR/CARs can be efficiently expressed at the surface of host cells and confer to host cells a diversified and highly sensitive signaling complex that acts with native host (e.g. T) cell signaling properties. Also provided are chimeric co-stimulatory receptor polypeptides (CCRs) that are capable of improving host cell (e.g. T cell) function when the host cell encounters PVR aka CD155. CCRs comprise an extracellular component (e.g. from CD226 or TIGIT) that is capable of binding to PVR and an intracellular component designed or selected to preserve normal CD226 signaling or disrupt or abrogate normal TIGIT signaling, such as by abrogating this signaling and/or by converting this signaling into an activating or co-stimulatory signal. Also provided are polynucleotides encoding the TCR/CARs and/or CCRs, and vectors that comprise the polynucleotides. Also provided are host cells, such as T cells, that encode or express the TCR/CARs and/or CCR. Also provided are compositions and methods for using the same the same.
BACKGROUND: Every human being has the right to affordable, high-quality health services. However, mothers and children in wealthier households worldwide have better access to healthcare and lower mortality rates than those in lower-income ones. Despite Somalia's fragile health system and the under-5 mortality rate being among the highest worldwide, it has made progress in increasing reproductive, maternal, and child health care coverage. However, evidence suggests that not all groups have benefited equally. We analysed secondary 2006 and 2018-19 data to monitor disparities in reproductive, maternal, and child health care in Somalia.
METHODS: The study's variables of interest are the percentage of contraceptive prevalence through modern methods, adolescent fertility rate, prenatal care, the rate of births attended by midwives, the rate of births in a health care facility, the rate of early initiation of breastfeeding, stunting and wasting prevalence and care-seeking for children under-five. As the outcome variable, we analysed the under-five mortality rate. Using reliable data from secondary sources, we calculated the difference and ratio of the best and worst-performing groups for 2006 and 2018-19 in Somalia and measured the changes between the two.
RESULTS: Between 2006 and 2018-19, An increase in the difference between women with high and low incomes was noticed in terms of attended labours. Little change was noted regarding socioeconomic inequities in breastfeeding. The difference in the stunting prevalence between the highest and lowest income children decreased by 20.5 points, and the difference in the wasting prevalence of the highest and the lowest income children decreased by 9% points. Care-seeking increased by 31.1% points. Finally, although under-five mortality rates have decreased in the study period, a marked income slope remains.
CONCLUSIONS: The study's findings indicate that Somalia achieved significant progress in reducing malnutrition inequalities in children, a positive development that may have also contributed to the decrease in under-five mortality rate inequities also reported in this study. However, an increase in inequalities related to access to contraception and healthcare for mothers is shown, as well as for care-seeking for sick children under the age of five. To ensure that all mothers and children have equal access to healthcare, it is crucial to enhance efforts in providing essential quality healthcare services and distributing them fairly and equitably across Somalia.
A total of 3 saliva samples will be collected from each patient - one at baseline preoperative, one intrapartum at least 15 min after starting the standard 250 ml/h oxytocin infusion, and one postpartum in post-anesthesia care unit (PACU) at least 15 min after starting the standard 125 ml/h oxytocin infusion. Therefore, the last collection point (sample 3) will be during the oxytocin infusion in PACU. In addition, 1 blood sample will be collected from each patient in this cohort - at same time as last saliva sample.
Recent studies have linked elevated tumor aneuploidy to anti-tumor immune suppression and adverse survival following immunotherapy. Herein, we provide supportive evidence for tumor aneuploidy as a biomarker of response to immunotherapy in patients with non-small cell lung cancer (NSCLC). We identify a dose-response relationship between aneuploidy score and patient outcomes. In two independent NSCLC cohorts (n = 659 patients), we demonstrate a novel association between elevated aneuploidy and non-smoking-associated oncogenic driver mutations. Lastly, we report enrichment of TERT amplification and immune-suppressive phenotypes of highly aneuploid NSCLC. Taken together, our findings emphasize a potentially critical role for tumor aneuploidy in guiding immunotherapy treatment strategies.
There are described recombinant VH and VL domains of human antibodies that bind IL-13. A series of proteins characterised by three CDR in each VH/VL are described. Preferably the molecules are single chain Fv or antibody molecules. Nucleic acids expressing the VH and VL domains are selected from phage display libraries. Neutralization potency of the resulting scFv's was tested in TF proliferation assays. 
The fragments and antibodies showed efficacy for IL-13 binding in murine models of pulmonary inflammation, the primate (cynomolgus) model of dermal allergy, IgE release from B cells and histamine potentiation in Ca2+ signalling in smooth muscle. Mice transgenic for human IL-13 antibodies and epitope mapping studies are also described. It is envisaged that the anti I1-13 reagents may be used to treat asthma, atopic dermatitis, allergic rhinitis, fibrosis, IBS, or Hodgkin's lymphoma.
PCT No. PCT/JP95/00830 Sec. 371 Date Oct. 13, 1995 Sec. 102(e) Date Oct. 13, 1995 PCT Filed Apr. 26, 1995 PCT Pub. No. WO95/29934 PCT Pub. Date Nov. 9, 1995To provide a method of efficiently separate protective components of Bordetella pertussis. On the basis of differences in adsorbability to calcium phosphate gel formed by adding calcium ions to a Bordetella pertussis culture in the presence of excess phosphate ions, protective components of Bordetella pertussis are separated from the Bordetella pertussis culture. Traditionally, protective components of Bordetella pertussis have been separated using different purification methods for the respective components. According to the present invention, the use of the same means of purification for all subject components makes it possible to purify each component with high efficiency and high recovery rate, an aspect very advantageous for industrial production. It is also possible to efficiently produce an improved purified pertussis component vaccine comprising an effective combination of pertussis filamentous hemagglutinin (FHA), pertactin (PRN, 69K-OMP), pertussis fimbriae (FIM) and pertussis toxin (PT).
Participants in group L will receive a single injection for femoral nerve block combined with continuous femoral nerve block intra-operatively. The femoral nerve block will be performed before the induction of anesthesia on the leg to be operated. Then the patients were given the 2% lidocaine 10 ml and 1% ropivacaine 10 ml as initial dose,then,the patients will receive a continuous infusion of 0.15% ropivacaine at 15 ml/h.Intra-operatively, bispectral index score (BIS) was titrated with the adjusting of desflurane to maintain the index between 50-60.After the surgery,these patients will receive continuous femoral nerve analgesia till 3 days post-operatively( the loading dose was set at 5 ml of 0.15% ropivacaine followed by an infusion of 0.15% ropivacaine at 5 ml/h, with bolus of 5 ml and the lock time of 30 min).
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: group of inventions relates to field of preparations for tooth and oral cavity care. Claimed is oral composition which includes particles that have cores, containing zinc oxide or silicon dioxide, where external core surface is bound with bioadhesive polymer by means of linker containing aminosilicon group. Composition includes orally acceptable carrier and can be made in form of preparation for teeth care, dental dye, pastille or confectionary product. Also claimed are methods of oral cavity processing with application of claimed composition. ^ EFFECT: application of preparations which include said particles ensures inhibition or reduction of formation of deposit on oral cavity surface, as well as inhibiting or reduction of biofilm deposition or adhesion of microbes to oral cavity surface. ^ 13 cl, 1 tbl, 3 ex
The study aims to increase the capacity to identify and treat youths at clinical high-risk for psychosis (CHRp) across Sacramento, CA by disseminating and implementing in community mental health clinics (CMHCs) universal screening and a stepped-care, team-based intervention that includes training and ongoing support in a Cognitive Behavioral Therapy package called Cognitive Behavioral Case Management (CBCM). The study is being conducted in nine non-psychosis specialty CMHCs across 5 agencies, all of which treat young people with public insurance (Medi-Cal/Medicaid) or no insurance. All youths aged 12-25 will be screened when beginning care and those who screen positive and agree will be assessed by the only specialty early psychosis clinic in the county, at the University of California-Davis. Thus the study also aims to triage this limited resource of specialized early psychosis expertise. CHRp+ youth will then begin a 2 year stepped-care intervention at their CMHCs and can move to the early psychosis specialty clinic if they still meet CHRp criteria after 2 years or develop psychosis. The specialty early psychosis service provides ongoing support and consultation.
PROBLEM TO BE SOLVED: To obtain a new compound having strong inhibiting action on Na+/H+ exchange in a human or animal cell and having further high effect as a medicine such as preventing and therapeutic agent for cardiovascular diseases. SOLUTION: This compound is represented by formula I [R1 is a group of formula II or III (R5 and R6 are each H, a lower alkyl or the like; X is carbonyl or sulfonyl); R2 is an arylyl or heterocycle; (n) is 1-6] and its salt, e.g. [3-(2,5-dichlorothiophen-3-yl)-5-[2-(methylaminoethyl)- aminocarbonyl]benzoyl]guanidine dihydrochloride. The compound of formula I is obtained by reacting a compound of formula IV, its derivative or a salt thereof with a compound of formula V, its derivative or a salt thereof. The reaction is usually carried out in water and an organic solvent under cooling or under heating. Furthermore, when the compound of formula V is used in a form of a free acid or its salt, the reaction is preferably carried out in the presence of a condensing agent.
BACKGROUND AND PURPOSE: Parent artery atherosclerosis is an important aetiology of recent subcortical ischaemic stroke (RSIS). However, comparisons of RSIS with different degrees of parent artery atherosclerosis are lacking.
METHODS: Prospectively collected data from our multicentre cohort (all were tertiary centres) of the Stroke Imaging Package Study between 2015 and 2017 were retrospectively reviewed. The patients with RSIS defined as a single clinically relevant diffusion-weighted imaging positive lesion in the territory of lenticulostriate arteries were categorized into three subgroups: (1) normal middle cerebral artery (MCA) on magnetic resonance angiography and high-resolution magnetic resonance imaging (HR-MRI); (2) low-grade MCA atherosclerosis (normal or <50% stenosis on magnetic resonance angiography and with MCA plaques on HR-MRI); (3) steno-occlusive MCA atherosclerosis (stenosis ≥50% or occlusion). The primary outcome was 90-day functional dependence (modified Rankin Scale score >2). The clinical and imaging findings were compared between subgroups.
RESULTS: A total of 239 patients (median age 60.0 [52.0-67.0] years, 72% male) were enrolled, including 140 with normal MCA, 64 with low-grade MCA atherosclerosis and 35 with steno-occlusive MCA atherosclerosis. Patients with steno-occlusive MCA atherosclerosis had the largest infarct volume. Low-grade MCA atherosclerosis was independently associated with cerebral microbleeding, more severe perivascular spaces in basal ganglia and higher total cerebral small vessel disease burden. Low-grade MCA atherosclerosis was an independent determinant of 90-day functional dependence (odds ratio 3.897; 95% confidence interval 1.309-11.604).
CONCLUSIONS: Our study suggested RSIS with varying severity of parent artery atherosclerosis exhibits distinctive clinical and neuroimaging characteristics, with low-grade MCA atherosclerosis associating with higher cerebral small vessel disease burden and worse prognosis.
The results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trial demonstrated the effectiveness of divalproex sodium extended-release tablets in the prophylactic treatment of migraine headache. This trial recruited patients with a history of migraine headaches with or without aura occurring on average twice or more a month for the preceding three months. Patients with cluster or chronic daily headaches were excluded. Women of childbearing potential were allowed in the trial if they were deemed to be practicing an effective method of contraception.

Patients who experienced ≥ 2 migraine headaches in the 4-week baseline period were randomized in a 1:1 ratio to divalproex sodium extended-release tablets or placebo and treated for 12 weeks. Patients initiated treatment on 500 mg once daily for one week, and were then increased to 1,000 mg once daily with an option to permanently decrease the dose back to 500 mg once daily during the second week of treatment if intolerance occurred. Ninety-eight of 114 divalproex sodium extended-release-treated patients (86%) and 100 of 110 placebo-treated patients (91%) treated at least two weeks maintained the 1,000 mg once daily dose for the duration of their treatment periods. Treatment outcome was assessed on the basis of reduction in 4-week migraine headache rate in the treatment period compared to the baseline period.

Patients (50 male, 187 female) ranging in age from 16 to 69 were treated with divalproex sodium extended release tablets (N=122) or placebo (N=115). Four patients were below the age of 18 and 3 were above the age of 65. Two hundred and two patients (101 in each treatment group) completed the treatment period. The mean reduction in 4-week migraine headache rate was 1.2 from a baseline mean of 4.4 in the divalproex sodium extended release tablets group, versus 0.6 from a baseline mean of 4.2 in the placebo group. The treatment difference was statistically significant (see Figure 3). 

Figure 3 Mean Reduction In 4-Week Migraine Headache Rates
During each sonogram in which cervical lengths are measured, 5 additional cervical indices will be collected using Samsung's E-cervix technology. Each index will then be separated based on characteristics to create a nomogram for singletons, twins, and those with interventions already in place (i.e. cerclage and/or progesterone) at the time of their E-cervix assessment.
<P>PROBLEM TO BE SOLVED: To provide a cosmetic and a skin preparation for external use blended with a poly-γ-L-glutamic acid-crosslinked material and/or its salt and an anti-aging agent, without having stickiness and excellent in refreshing feeling.  <P>SOLUTION: This cosmetic composition containing the poly-γ-L-glutamic acid-crosslinked material and anti-aging agent is provided by without having stickiness and excellent in refreshing feeling while maintaining the effect of the anti-aging agent. The anti-aging agent may be an anti-inflammatory agent and/or an antioxidant. Further, the cosmetic composition may contain a humectant, an ultraviolet light absorbent, and/or an antibacterial agent. The cosmetic composition can be utilized as a cosmetic, quasi-drug, medical supply, hygienic material or medicine.  <P>COPYRIGHT: (C)2010,JPO&INPIT
A radiopaque composition for use in visualizing and cleaning root canal system anatomy, pathologies, anomalies, and iatrogenic conditions. The composition comprises a radiopaque iodine solution and a sodium hypochlorite solution. The iodine solution comprises diatrizoate maglumine and sodium iodine. The iodine solution and sodium hypochlorite solution are mixed in a ratio of between 5:95 to 95:5, by volume. Preferably, the iodine solution and sodium hypochlorite solution are mixed in a ratio of between 30:70 to 70:30, by volume. And more preferably, the iodine solution and sodium hypochlorite solution are mixed in a ratio of between 45:55 to 55:45, by volume. In use, the root canal system anatomy, anomaly, pathology, or iatrogenic condition to be visualized and addressed or treated is liberally flushed with the composition, preferably after the root canal system has been exposed. The sodium hypochlorite in the composition will digest pulp in the canal system and destroy and remove any organisms and irritants residing in or on the anatomy, anomaly or pathology. The iodine in the solution will enable a dentist to take a high contrast X-ray to visualize the anatomy, anomaly, pathology, or iatrogenic event in three-dimensions. The solution is particularly effective for visualizing root canal systems.
The present technology provides a composition for improving brain function. A composition for improving brain function, which comprises acetic acid and/or an acetate salt as an active ingredient. Further, the improvement of brain function is preferably improvement of brain dysfunction or improvement of cognitive dysfunction. Further, the cognitive dysfunction is preferably dementia of the alzheimer's type or vascular dementia. Further, it is preferably used for oral ingestion. Further, the composition is preferably a food or beverage composition for improving brain function.
The magnets used in the current study consists of a mother and daughter magnets. An 8-Fr nasogastric tube is tightly fixed with the mother magnet, which will be used for bile or pancreatic drainage before formation of anastomoses. The outside diameter (OD) of the magnets ranges from 5mm to 15mm. In fact, for biliojejunostomy, larger magnets are applied, whereas for pancreaticojejunostomy, smaller magnets are routinely used. This study is a single-center, parallel controlled trial to evaluate the safety and effectiveness of magnetic compression technique for biliojejunostomy and pancreaticojejunostomy, versus traditional hand-sewn techniques on the postoperative morbidity of the patients. And also how to avoid mutual attraction of the two pairs of magnets, formation of bilio-/pancreaticojejunostomy time, discharge rule of the magnets will be all evaluated in the current study.
Studies 301A and 303 - Treatment Emergent Adverse Reactions: The most common adverse reactions that occurred in patients receiving EMTRIVA with other antiretroviral agents in clinical studies 301A and 303 were headache, diarrhea, nausea, and rash, which were generally of mild to moderate severity. Approximately 1% of patients discontinued participation in the clinical studies due to these events. All adverse reactions were reported with similar frequency in EMTRIVA and control treatment groups with the exception of skin discoloration which was reported with higher frequency in the EMTRIVA treated group. 

Skin discoloration, manifested by hyperpigmentation on the palms and/or soles was generally mild and asymptomatic. The mechanism and clinical significance are unknown.

A summary of EMTRIVA treatment emergent clinical adverse reactions in studies 301A and 303 is provided in Table 2.